Onconetix, Inc. filed a Form 425 on October 27, 2026, sharing details of acquisition target Realbotix's launch of its Echo humanoid robot platform in connection with the company's pending all-stock acquisition of Realbotix LLC.

Key Highlights

  • Two models announced: Realbotix launched the Echo Tabletop, priced at $11,950, and the Echo Full Body, priced at $59,950, on October 26, 2026.
  • Initial production run: 225 Echo Tabletop units and 25 Echo Full Body units, with delivery anticipated in the second half of 2027.
  • Pending acquisition: Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC on February 12, 2026.
  • All-stock transaction: The deal is structured as an all-stock transaction, with the combined company expected to trade on Nasdaq following closing.
  • Closing conditions: The transaction is subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

Onconetix Shares Realbotix Echo Robot Launch Ahead of Pending Acquisition

According to the filing, Onconetix, Inc. (NASDAQ:ONCO) issued this Form 425 communication to inform its shareholders about a product launch by Realbotix, the target of its pending acquisition. On October 26, 2026, Realbotix Corp. announced the official launch of Echo, a new humanoid robot platform offered in two configurations. The filing describes the Echo Tabletop at $11,950 and the Echo Full Body at $59,950, with an initial production run consisting of 225 Tabletop units and 25 Full Body units, delivery anticipated in the second half of 2027.

The filing notes that Onconetix previously entered into a definitive share exchange agreement on February 12, 2026, to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp. The transaction is structured as an all-stock deal. According to the filing, the combined company is expected to trade on Nasdaq following closing, which remains subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

The filing identifies Onconetix as "a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions," and notes that it owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union. Realbotix LLC is described in the filing as a developer of "AI-powered humanoid robots designed for human interaction across enterprise and consumer environments," manufactured in the United States. The filing states it is provided for informational purposes only and cautions investors not to place undue reliance on forward-looking or projected information, noting that such statements are subject to the company's own cautionary language and risk factors.

What Was Disclosed

Onconetix filed a Form 425 disclosing that its acquisition target, Realbotix, launched the Echo humanoid robot line in two priced models with an initial 250-unit production run, and reaffirmed the terms and pending status of its all-stock acquisition of Realbotix LLC.